Publications by authors named "A Saraste"
Fibrosis is one of the key healing responses to injury, especially within the heart where it helps to maintain structural integrity following acute insults such as myocardial infarction. However, if it becomes dysregulated then fibrosis can become maladaptive leading to adverse remodelling, impaired cardiac function and heart failure. Fibroblast activation protein is exclusively expressed by activated fibroblasts, the key effector cells of fibrogenesis, and has a unique extracellular domain that is an ideal ligand for novel molecular imaging probes.
View Article and Find Full Text PDFArticle Synopsis
- * Researchers administered low doses of AdVammin through a catheter into the pig hearts, observing an increase in capillary size and improved heart function, as indicated by higher ejection fractions during stress tests.
- * However, the therapy also led to increased tissue permeability and fluid buildup around the heart, suggesting that proper dosage is crucial for maximizing therapeutic benefits.
Hybrid cardiovascular imaging. A clinical consensus statement of the european association of nuclear medicine (EANM) and the european association of cardiovascular imaging (EACVI) of the ESC.
Eur J Nucl Med Mol Imaging
October 2024
Article Synopsis
- - Hybrid imaging combines two or more imaging techniques to enhance image quality and information, particularly in cardiovascular applications.
- - This imaging can involve either merging images from separate scanners or using advanced hybrid machines like PET/CT and PET/MR.
- - The European associations aim to assess clinical scenarios that could benefit from this technology and suggest best practices for obtaining diagnostic images.
Background: Despite tremendous therapeutic advancements, a significant proportion of coronary artery disease patients suffer from refractory angina pectoris, that is, quality-of-life-compromising angina that is non-manageable with established pharmacological and interventional treatment options. Adenoviral vascular endothelial growth factor-D (AdVEGF-D)-encoding gene therapy (GT) holds promise for the treatment of refractory angina.
Methods: ReGenHeart is an investigator-initiated, multicentre, randomised, placebo-controlled and double-blinded phase 2 clinical trial that aims to study the safety and efficacy of intramyocardially administered angiogenic AdVEGF-D GT for refractory angina.